0
12 3
456
789
week
Very Poor Response(≥50% viable tumor)
P/A
M I/P
M I/A
M P/A
M
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
week I/P
M I/A
26 27 28 29 30
M=High-Dose-Methotrexat A=Doxorubicin P=Cisplatin I=Ifosfamide
Patients without primary surgery:Neoadjuvant and adjuvant chemotherapy
P/A
I/P
I/A
P/A
I/P
I/A
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
week
P/A
I/P
I/A
op week
…… inf inf inf inf
30 31 32 33
101 102 103 104
AP
M M AP
M M OP
1 2 3 4 5 6 7 8 9 10 11
poor response
MAP
AP
M M AP
MMA
MMA
MM
12
ran domize
13 14 15 16 17
18 19 20 21 22 23 24 25 26 27 28 29
EOI, European Osteosacroma Intergroup; CCG, Childern’s cancer group; SSG, scandinavian sarcoma group; COSS, Cooperative Osteosacroma study group; MTX, high dose methotrexate ; CDP, cisplatin; ADM, doxorubicin. BCD, bleomycin ; cyclophosphamide, dactinomycin; IFO, ifosfamide; DFS, disease-free survival; PFS, progression-free survival; RFS, relapse-free survival; EFS, event-free survival;